A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Trial Identifier: D3461C00040
Sponsor: AstraZeneca
Collaborator:
ICON
Start Date: April 2026
Primary Completion Date: January 2029
Study Completion Date: January 2029
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.